TFX Stock Analysis — Teleflex Incorporated
Sector: Healthcare
AI Verdict
Teleflex trades at 15.4x next year's earnings—cheap for healthcare—but with negative revenue growth, you're betting the hospital device moat can reignite demand before the market loses patience.
Competitive Moat
Teleflex designs and manufactures medical devices for critical care and surgical applications, with a defensible moat built on regulatory approvals and embedded hospital relationships that create high switching costs. Its portfolio of proprietary catheter and vascular access products makes it difficult for competitors to displace them in core hospital settings.
Summary
TFX stands out for its entrenched hospital device portfolio, but faces questions as revenue shrinks.
Where It Stands
Teleflex trades at 15.4x next year's earnings, below the healthcare sector median of 22x, while trailing revenue growth is negative at -2.8%.
Key Metrics
- Forward P/E: 15.4x
- Revenue Growth: -0.0%
- Dividend Yield: 0.01%
- 52-Week High: $139.67
- 52-Week Low: $100.18
Analyst Consensus
5 Buy · 12 Hold · 0 Sell (17 analysts)
Bull Case
A forward P/E of 15.4x is a discount to the sector, suggesting the market is pricing in little for any recovery despite Teleflex's sticky hospital device business.
Bear Case
With revenue shrinking -2.8% year-over-year, even a modest P/E re-rating to the sector median would require a reversal in growth that isn't yet visible.
Catalyst to Watch
Watch for upcoming earnings or regulatory approvals that could signal a turnaround in revenue growth.